CA3025492A1 - Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto - Google Patents

Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto Download PDF

Info

Publication number
CA3025492A1
CA3025492A1 CA3025492A CA3025492A CA3025492A1 CA 3025492 A1 CA3025492 A1 CA 3025492A1 CA 3025492 A CA3025492 A CA 3025492A CA 3025492 A CA3025492 A CA 3025492A CA 3025492 A1 CA3025492 A1 CA 3025492A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
independently selected
compound according
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3025492A
Other languages
English (en)
French (fr)
Inventor
M. Arshad Siddiqui
Stephane Ciblat
Martin DERY
Lea CONSTANTINEAU-FORGET
Chantal Grand-Maitre
Xiangyu GUO
Sanjay Srivastava
Gerald W. Shipps
Alan B. Cooper
Nicolas BRUNEAU-LATOUR
Vu Linh Ly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of CA3025492A1 publication Critical patent/CA3025492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3025492A 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto Abandoned CA3025492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
US62/169,376 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
CA3025492A1 true CA3025492A1 (en) 2016-12-08

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025492A Abandoned CA3025492A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Country Status (9)

Country Link
US (2) US10537558B2 (enExample)
EP (1) EP3303332A1 (enExample)
JP (1) JP6707630B2 (enExample)
CN (1) CN108349962A (enExample)
BR (1) BR112017025851A2 (enExample)
CA (1) CA3025492A1 (enExample)
IL (1) IL255898A (enExample)
MX (1) MX2017015456A (enExample)
WO (1) WO2016196644A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015456A (es) 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
MX2019006296A (es) 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
WO2018102453A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
CN111918865B (zh) 2018-03-30 2023-10-27 住友化学株式会社 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物
JP2021527059A (ja) * 2018-06-07 2021-10-11 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
US12358905B2 (en) * 2019-05-31 2025-07-15 Bantam Pharamceutical, LLC Methods for making thiazolypyrazole carboxylic acids and intermediates therefor
US12435076B2 (en) 2019-11-01 2025-10-07 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound and method for producing same
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
TW202315621A (zh) 2021-08-25 2023-04-16 美商皮克醫療公司 Eif4e抑制劑及其用途
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
ATE252576T1 (de) * 1999-12-03 2003-11-15 Pfizer Prod Inc Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
US6900219B2 (en) 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
CA2520870A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20070060584A1 (en) * 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
AR068063A1 (es) * 2007-08-27 2009-11-04 Basf Plant Science Gmbh Co mpuestos de pirazol para controlar plagas de invertebrados
WO2009123316A1 (ja) * 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
HRP20150842T1 (hr) 2008-04-28 2015-09-11 Kyorin Pharmaceutical Co., Ltd. Derivati ciklopentilakrilamida
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
CA2888889A1 (en) 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
CN106458992B (zh) 2014-03-27 2019-03-15 默克专利股份公司 吡啶基哌啶
JP2018513870A (ja) 2015-04-24 2018-05-31 シンジェンタ パーティシペーションズ アーゲー 硫黄置換5員環複素環を有する殺有害生物的に活性な多環式誘導体
MX2017015456A (es) 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Also Published As

Publication number Publication date
US20180311218A1 (en) 2018-11-01
IL255898A (en) 2018-01-31
WO2016196644A1 (en) 2016-12-08
CN108349962A (zh) 2018-07-31
US10537558B2 (en) 2020-01-21
JP2018521119A (ja) 2018-08-02
US11602526B2 (en) 2023-03-14
EP3303332A1 (en) 2018-04-11
JP6707630B2 (ja) 2020-06-10
US20200261424A1 (en) 2020-08-20
BR112017025851A2 (pt) 2018-10-16
MX2017015456A (es) 2018-11-29

Similar Documents

Publication Publication Date Title
US11602526B2 (en) Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
JP7775430B2 (ja) Irak4阻害剤としての二環式ヘテロシクリル誘導体
US12150934B2 (en) Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
AU2014241152A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
EP2102199A1 (en) Antibacterial polycyclic urea compounds
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators
KR102414365B1 (ko) 신규 화합물 및 그의 약리적으로 허용가능한 염
CA2962312A1 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
AU2015242219A1 (en) Sulfonamide compounds as Voltage gated sodium channel modulators
IL322435A (en) Covalent modifiers of Akt1 and their uses
CA2810489A1 (en) Prostaglandin d synthase inhibitory piperidine compounds
CN108373476B (zh) 一种激酶抑制剂及其制备和应用
AU2016378154B2 (en) Phenylimidazole compound
CN112939966B (zh) 嘧啶衍生物、其制备及应用
CN120359220A (zh) 苯并咪唑衍生物
TW202519208A (zh) 用於治療用途的糖原合酶激酶3的抑制劑

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220823